FDA granted Priority Review to venetoclax for the treatment of chronic lymphocytic leukemia in adults who have received at least one prior therapy, including patients with 17p deletion.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
